Study to Test the Combination of Voriconazole and Anidulafungin in Patients Who Have, or Are Thought to Have, Invasive Aspergillosis and Who Are Unable to Take a Common Antifungal Therapy (Polyene)

• Drug: voriconazole
  
  Subjects with creatinine clearance at least 50 ml/min will receive initial treatment with IV (loading dose of 6 mg/kg Q12h followed by maintenance dose of 4 mg/kg Q12h) or oral (loading dose of 400 mg Q12h followed by maintenance dose of 300 mg Q12h). Subjects with creatinine clearance <50 ml/min will receive oral voriconazole (loading dose of 400 mg Q12h followed by maintenance dose of 300 mg Q12h).
  Other Name: Vfend
• Drug: anidulafungin
  
  Loading dose of 200 mg QD followed by maintenance dose of 100 mg QD for up to a total of 28 days therapy
  Other Name: Eraxis

• Experimental: combination 2
  
  anidulafungin plus voriconazole
  Intervention: Drug: voriconazole
• Experimental: combination 1
  
  anidulafungin plus voriconazole
  Intervention: Drug: anidulafungin

Inclusion Criteria:

Proven or probable invasive aspergillosis. Patient is intolerant to polyene therapy.

Exclusion Criteria:

Patients with invasive aspergillosis for more than 30 days at the time of study entry. Patients with uncontrolled bacterial or viral infection at the time of study entry. Patients with significant liver dysfunction or who are taking certain medications which interact with voriconazole.